Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BerGenBio AS (DE:7BG)
BERLIN:7BG
Holding DE:7BG?
Track your performance easily
7BG Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.90 - €3.08
Previous Close€1.08
Volume0.00
Average Volume (3M)30.00
Market Cap
€48.25M
Enterprise Value€425.15M
Total Cash (Recent Filing)kr0.00
Total Debt (Recent Filing)kr407.83M
Price to Earnings (P/E)―
Beta7.57
Next Earnings
Aug 21, 2024EPS Estimate
-€10.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,688,689,214
10 Day Avg. Volume0
30 Day Avg. Volume30
Standard Deviation0.71
R-Squared0.00006
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)0.00300
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.10Price Target Upside463.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BerGenBio AS News
PremiumCompany Announcements
BerGenBio Advances in Lung Cancer Therapy
PremiumCompany Announcements
BerGenBio Advances Lung Cancer Therapy ResearchPremiumCompany Announcements
BerGenBio ASA Completes Share Capital Increase
7BG FAQ
What was BerGenBio AS’s price range in the past 12 months?
BerGenBio AS lowest stock price was €0.90 and its highest was €3.08 in the past 12 months.
What is BerGenBio AS’s market cap?
Currently, no data Available
When is BerGenBio AS’s upcoming earnings report date?
BerGenBio AS’s upcoming earnings report date is Aug 21, 2024 which is 36 days ago.
How were BerGenBio AS’s earnings last quarter?
BerGenBio AS released its earnings results on May 29, 2024. The company reported -€0.087 earnings per share for the quarter, beating the consensus estimate of -€0.174 by €0.087.
Is BerGenBio AS overvalued?
According to Wall Street analysts BerGenBio AS’s price is currently Undervalued.
Does BerGenBio AS pay dividends?
BerGenBio AS does not currently pay dividends.
What is BerGenBio AS’s EPS estimate?
BerGenBio AS’s EPS estimate is -€10.89.
How many shares outstanding does BerGenBio AS have?
Currently, no data Available
What happened to BerGenBio AS’s price movement after its last earnings report?
BerGenBio AS reported an EPS of -€0.087 in its last earnings report, beating expectations of -€0.174. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of BerGenBio AS?
Currently, no hedge funds are holding shares in DE:7BG
---
BerGenBio AS Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.10 (463.04% Upside)
€6.10 (463.04% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.87%
12-Months-Change
Fundamentals
Return on Equity
-280.05%
Trailing 12-Months
Asset Growth
52.71%
Trailing 12-Months
Company Description
BerGenBio AS
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
---
7BG Company Deck
---
7BG Earnings Call
Q1 2024
0:00 / 0:00
---
7BG Stock 12 Month Forecast
Average Price Target
€6.10
▲(463.04% Upside)
Technical Analysis
Best Analysts Covering 7BG
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-38.78%
reiterated a buy rating 4 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.78% per trade.
---